FMP

FMP

Sportradar Group AG's Financial Performance Compared to Peers

- (Last modified: Aug 22, 2025 1:33 PM)

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • Sportradar Group AG (NASDAQ:SRAD) has a Return on Invested Capital (ROIC) of 6.08%, which is lower than its Weighted Average Cost of Capital (WACC) of 14.17%, indicating inefficiency in generating returns that exceed its cost of capital.
  • Competitors like Genius Sports Limited and Thoughtworks Holding, Inc. also struggle with negative ROIC values, suggesting a common challenge in the sports data and technology sector in surpassing their cost of capital.

Sportradar Group AG (NASDAQ:SRAD) is a leading global provider of sports data and content. The company offers a range of services, including data analytics, sports entertainment, and betting services. It competes with other companies in the sports data and technology sector, such as Genius Sports Limited and Thoughtworks Holding, Inc.

Sportradar's Return on Invested Capital (ROIC) is 6.08%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 14.17%. This indicates that the company is not currently generating returns that exceed its cost of capital. The ROIC to WACC ratio of 0.43 further highlights this inefficiency in capital utilization.

In comparison, Genius Sports Limited has a negative ROIC of -13.85% and a WACC of 12.60%, resulting in a ROIC to WACC ratio of -1.10. This suggests that Genius Sports is also struggling to generate returns above its cost of capital. Similarly, Thoughtworks Holding, Inc. has a ROIC of -3.79% and a WACC of 9.10%, leading to a ROIC to WACC ratio of -0.42.

Clearwater Analytics Holdings, Inc. and PowerSchool Holdings, Inc. also show inefficiencies in capital utilization, with ROIC to WACC ratios of -0.04 and 0.08, respectively. However, Mister Car Wash, Inc. stands out with a ROIC of 4.67% and a WACC of 6.90%, resulting in the highest ROIC to WACC ratio of 0.68 among the peers.

Other Blogs

Aug 21, 2025 4:00 PM - Alex Lavoie

Protalix BioTherapeutics, Inc. (AMEX:PLX) Financial Efficiency Analysis

Protalix BioTherapeutics, Inc. (AMEX:PLX) is a biopharmaceutical company that focuses on the development and commercialization of recombinant therapeutic proteins. These proteins are produced using its proprietary ProCellEx plant cell-based protein expression system. The company operates in a compet...

blog post title

Aug 21, 2025 4:00 PM - Alex Lavoie

Coherus BioSciences, Inc. (NASDAQ:CHRS) Demonstrates Strong Financial Performance

Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company that focuses on developing and commercializing biosimilar drugs. These are drugs that are highly similar to already approved biological medicines, offering more affordable treatment options. Coherus competes with other biopharmac...

blog post title